Pelthos Therapeutics Reports $10.9M Revenue in Q1 2026, Operating Loss of $13.1M

Pelthos Therapeutics Inc. reported a total revenue of $10.9 million for the first quarter of 2026, a significant increase from zero revenue in the same period of the previous year. This revenue primarily stems from net product sales of ZELSUVMI, a topical gel for treating molluscum contagiosum, which was launched in July 2025. The company also generated $241,000 in license and collaboration revenues, marking its first recognition of such income. However, Pelthos incurred an operating loss of $13.1 million, compared to a loss of $1.8 million in the prior year, largely due to increased selling, general, and administrative expenses, which rose to $21.1 million from $1.6 million.

The company's financial position has improved, with cash and cash equivalents increasing to $32.0 million as of March 31, 2026, up from $18.0 million at the end of 2025. Total assets also grew to $145.4 million, compared to $130.4 million at the end of the previous fiscal year. The increase in cash was bolstered by a $30 million drawdown from a Venture Loan and Security Agreement, which allows for an additional $20 million contingent on achieving certain milestones. The company’s total liabilities rose to $110.3 million, primarily due to the convertible debt and the venture loan.

Operationally, Pelthos has made significant strides since its merger with LNHC on July 1, 2025. The company now has three FDA-approved products in its portfolio: ZELSUVMI, XEPI, and XEGLYZE. The acquisition of XEPI and XEGLYZE in late 2025 is expected to enhance its commercial offerings. As of March 31, 2026, Pelthos had approximately 64 territory managers focused on the commercialization of ZELSUVMI, and it plans to relaunch XEPI in early 2027 after completing necessary regulatory and supply chain activities.

The company reported a net loss of $10.2 million for the first quarter of 2026, which reflects the costs associated with its commercial launch and ongoing operational expenses. The increase in SG&A expenses is attributed to the expansion of its sales force and marketing efforts for ZELSUVMI. Looking ahead, Pelthos anticipates that its financial performance will be driven by the successful commercialization of its products and the potential for additional revenue from its licensing agreements. Management believes it has sufficient capital to fund operations for at least the next twelve months, although it may need to raise additional funds to support future growth initiatives.